• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Oseltamivir dosing in premature infants.早产儿奥司他韦的剂量。
J Infect Dis. 2012 Sep 15;206(6):847-50. doi: 10.1093/infdis/jis471. Epub 2012 Jul 17.
2
The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.应用群体药代动力学方法探讨流感感染婴儿奥司他韦的剂量。
Clin Pharmacol Ther. 2014 Sep;96(3):380-9. doi: 10.1038/clpt.2014.120. Epub 2014 May 27.
3
Oseltamivir dosing for influenza infection in premature neonates.奥司他韦治疗早产儿流感感染的剂量。
J Infect Dis. 2010 Aug 15;202(4):563-6. doi: 10.1086/654930.
4
Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.开放标签研究中静脉注射奥司他韦在婴幼儿和儿童中的药代动力学及安全性
Int J Clin Pharmacol Ther. 2015 Jul;53(7):531-40. doi: 10.5414/CP202307.
5
Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.确定新的口服奥司他韦（神经氨酸酶抑制剂）剂量方案，用于中度和重度肾功能损害的患者。
Clin Pharmacol Drug Dev. 2015 Sep;4(5):326-36. doi: 10.1002/cpdd.203. Epub 2015 Jul 2.
6
Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.奥司他韦及其羧酸代谢产物的机制人群药代动力学模型，考虑到生理变化以预测新生儿和婴儿的暴露情况。
Clin Pharmacol Ther. 2020 Jul;108(1):126-135. doi: 10.1002/cpt.1791. Epub 2020 Feb 26.
7
Lack of unwanted effects of oseltamivir carboxylate in juvenile rats after subcutaneous administration.羧基奥司他韦皮下注射后在幼年大鼠中无不良作用。
Basic Clin Pharmacol Toxicol. 2012 Jun;110(6):551-3. doi: 10.1111/j.1742-7843.2011.00840.x. Epub 2011 Dec 29.
8
Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.口服和静脉注射奥司他韦治疗需器官替代治疗的重症乙型流感病毒感染的药代动力学
Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):155-164. doi: 10.1007/s13318-016-0330-9.
9
A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers.一项针对健康泰国志愿者的75毫克口服磷酸奥司他韦两种剂型的随机、开放标签、两周期交叉生物等效性研究。
Int J Clin Pharmacol Ther. 2008 Dec;46(12):654-62. doi: 10.5414/cpp46654.
10
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.重症患者接受连续静脉-静脉血液透析和/或体外膜氧合时奥司他韦和奥司他韦羧酸的药代动力学。
Pharmacotherapy. 2012 Dec;32(12):1061-9. doi: 10.1002/phar.1151.

本文引用的文献

1
Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.在新生儿后期，羧酸酯酶 1 的表达激增，使迅速获得激活抗流感前药奥司他韦的能力。
J Infect Dis. 2011 Apr 1;203(7):937-42. doi: 10.1093/infdis/jiq145.
2
Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).抗流感病毒药物的治疗和化学预防 --- 免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2011 Jan 21;60(1):1-24.
3
Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak.奥司他韦治疗和预防在新生儿重症监护病房在 2009 年 H1N1 流感爆发。
J Perinatol. 2011 Jul;31(7):487-93. doi: 10.1038/jp.2010.159. Epub 2011 Jan 13.
4
Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.奥司他韦处置的药理学考虑因素：重点关注新生儿和婴儿。
Paediatr Drugs. 2011 Feb 1;13(1):19-31. doi: 10.2165/11536950-000000000-00000.
5
Oseltamivir dosing for influenza infection in premature neonates.奥司他韦治疗早产儿流感感染的剂量。
J Infect Dis. 2010 Aug 15;202(4):563-6. doi: 10.1086/654930.
6
Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis.奥司他韦治疗小于 1 岁婴儿流感：回顾性分析。
Pediatr Infect Dis J. 2010 Jun;29(6):495-8. doi: 10.1097/INF.0b013e3181cc4d01.
7
Influenza-associated deaths among children in the United States, 2003-2004.2003 - 2004年美国儿童流感相关死亡情况
N Engl J Med. 2005 Dec 15;353(24):2559-67. doi: 10.1056/NEJMoa051721.
8
Experience with oseltamivir for infants younger than 1 year old in Japan.日本使用奥司他韦治疗1岁以下婴儿的经验。
Pediatr Infect Dis J. 2005 Jun;24(6):575-6. doi: 10.1097/01.inf.0000164799.33635.fe.
9
Resistant influenza A viruses in children treated with oseltamivir: descriptive study.接受奥司他韦治疗的儿童中的甲型流感病毒耐药性：描述性研究
Lancet. 2004;364(9436):759-65. doi: 10.1016/S0140-6736(04)16934-1.
10
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.抗流感前体药物奥司他韦在1至5岁儿童中的药代动力学
Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. doi: 10.1007/s00228-003-0639-6. Epub 2003 Aug 9.

早产儿奥司他韦的剂量。

Oseltamivir dosing in premature infants.

机构信息

Department of Pharmacy, St. Louis Children's Hospital, St. Louis, MO 63110, USA.

出版信息

J Infect Dis. 2012 Sep 15;206(6):847-50. doi: 10.1093/infdis/jis471. Epub 2012 Jul 17.

DOI:10.1093/infdis/jis471
PMID:22807525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3572879/
Abstract

We conducted a 2-sample pharmacokinetic study of oseltamivir in 12 premature infants. Oseltamivir 1 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n=8) resulted in oseltamivir carboxylate exposure comparable to previously published pediatric data, which helps prospectively validate this regimen. Oseltamivir 3 mg/kg/dose once daily in premature infants >38 weeks postmenstrual age (born prematurely but chronologically past term, n=4) resulted in similar oseltamivir and oseltamivir carboxylate exposure. Although these results suggest persistence of immature renal function in this subgroup, further pharmacokinetic/pharmacodynamic description is required to confirm the appropriateness of this regimen.

摘要

我们对 12 名早产儿进行了奥司他韦的两样本药代动力学研究。对于<38 周龄的婴儿（n=8），每日两次给予奥司他韦 1mg/kg 剂量，其奥司他韦羧酸的暴露量与先前发表的儿科数据相当，这有助于前瞻性验证该方案。对于>38 周龄的早产儿（虽然早产，但已过预产期，n=4），每日一次给予奥司他韦 3mg/kg 剂量，奥司他韦和奥司他韦羧酸的暴露量相似。尽管这些结果表明该亚组的肾功能不成熟持续存在，但需要进一步的药代动力学/药效学描述来确认该方案的适当性。